CellPryme-M question, page-12

Afternoon Shell.

If your talking about Peter MacCallum CAR-T programs external to OmniCar, not sure.

As wonderful as Peter MacCallum are, it's probably worth noting that the bulk of the stealth program was developed using Carina Biotech facilities.

So as for Peter MacCallum paying to license CellPryme, perhaps being such close collaborators with PTX there is a mutually beneficial arrangement in return for CellPryme use?

Perhaps Peter MacCallum give PTX concessions on use of facilities etc in return for licenses? I've no doubt that whilst Peter MacCallum is in pure pursuit of life changing advancements in cancer therapy, PTX would be paying for the use of Peter Mac facilities & either paying the entire wages of the 4x full-time technician or subsidising them.

Whilst nothing is free, the real blessing is Peter MacCallum want to partner with PTX. You can't buy your way in, you need genuine programs of merit with solid management I'd imagine if Peter MacCallum are to open their doors and resources.

As for the last posters question tòo, I couldn't imagine CellPryme requiring specific tools that we'd sell. It sounds more IP based, a simple technique adjustment during the manufacturing process that can easily be adapted by 3rd party in their current labs.

But don't worry, I think there will be very good coin for PTX shareholders in just the simple licensing of CellPryme. It's a fast growing therapy, only going to explode in years to come and I see it as been a very good earner for PTX. Might help subsidise our future registrational trials for OmniCar, PTX-100 & PTX-200 whilst keeping the share register tight.